(Q51912769)

17 April 2018

title

Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients. (English)

1 reference

17 April 2018

main subject

anti-retroviral agent

0 references

author name string

Jörg Ruof

1

1 reference

17 April 2018

Alexander Dusek

2

1 reference

17 April 2018

Michael DeSpirito

3

1 reference

17 April 2018

Ralph A Demasi

4

1 reference

17 April 2018

publication date

1 January 2007

1 reference

17 April 2018

Clinical Drug Investigation

published in

1 reference

17 April 2018

volume

27

1 reference

17 April 2018

issue

7

1 reference

17 April 2018

page(s)

469-479

1 reference

17 April 2018

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)

cites work

1 reference

12 December 2020

Rationale for new treatments aimed at IgE immunomodulation

1 reference

12 December 2020

CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy.

1 reference

12 December 2020

Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus

1 reference

12 December 2020

Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations

1 reference

12 December 2020

Fusion inhibition--a major but costly step forward in the treatment of HIV-1.

1 reference

12 December 2020

Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis

1 reference

12 December 2020

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

1 reference

12 December 2020

Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease

1 reference

12 December 2020

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

12 December 2020

The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS.

1 reference

12 December 2020

Adjusting for bias in C/E ratio estimates.

1 reference

12 December 2020

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

12 December 2020

Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.

1 reference

12 December 2020

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

1 reference

12 December 2020

Use of surrogate measures in cost-effectiveness analyses of lipid-lowering therapies

1 reference

12 December 2020

Distribution of health care expenditures for HIV-infected patients

1 reference

12 December 2020

Assessing the cost-effectiveness of HAART for adults with HIV in England

1 reference

12 December 2020

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

1 reference

12 December 2020

HIV infection--a new drug and new costs

1 reference

12 December 2020

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs

1 reference

12 December 2020

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

12 December 2020

10.2165/00044011-200727070-00004

Identifiers

DOI

1 reference

17 April 2018

1 reference

17 April 2018